NASDAQ:INDV Indivior (INDV) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free INDV Stock Alerts $17.58 +0.33 (+1.91%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$17.23▼$17.7950-Day Range$16.66▼$23.0052-Week Range$14.38▼$26.50Volume180,383 shsAverage Volume121,096 shsMarket Capitalization$2.42 billionP/E Ratio1,758.00Dividend YieldN/APrice Target$36.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Indivior alerts: Email Address Indivior MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside104.8% Upside$36.00 Price TargetShort InterestHealthy0.15% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.73Based on 7 Articles This WeekInsider TradingN/AProj. Earnings Growth27.59%From $2.03 to $2.59 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.84 out of 5 starsMedical Sector429th out of 914 stocksPharmaceutical Preparations Industry183rd out of 418 stocks 3.5 Analyst's Opinion Consensus RatingIndivior has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIndivior has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.15% of the float of Indivior has been sold short.Short Interest Ratio / Days to CoverIndivior has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Indivior has recently increased by 15.78%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldIndivior does not currently pay a dividend.Dividend GrowthIndivior does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INDV. Previous Next 1.3 News and Social Media Coverage News SentimentIndivior has a news sentiment score of -0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Indivior this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for INDV on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows6 people have added Indivior to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Indivior insiders have not sold or bought any company stock.Percentage Held by Institutions60.33% of the stock of Indivior is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Indivior are expected to grow by 27.59% in the coming year, from $2.03 to $2.59 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Indivior is 1,758.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 131.32.Price to Earnings Ratio vs. SectorThe P/E ratio of Indivior is 1,758.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 170.65.Price to Book Value per Share RatioIndivior has a P/B Ratio of 47.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Indivior Stock (NASDAQ:INDV)Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Read More INDV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INDV Stock News HeadlinesApril 26, 2024 | finance.yahoo.comIndivior PLC (INDV) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges with ...April 25, 2024 | msn.comINDV Stock Earnings: Indivior Misses EPS, Misses Revenue for Q1 2024April 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 25, 2024 | prnewswire.comIndivior Announces Q1 2024 Financial ResultsApril 18, 2024 | americanbankingnews.comIndivior (INDV) Scheduled to Post Earnings on ThursdayApril 4, 2024 | msn.comAddex spinoff Neurosterix debuts with $63m for developing neurological therapiesApril 4, 2024 | wsj.comIndivior PLCMarch 11, 2024 | prnewswire.comIndivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal NaloxoneApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 8, 2024 | bizjournals.comFDA inspection flags public company's Raleigh facilityFebruary 29, 2024 | prnewswire.comCourt Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict LitigationFebruary 25, 2024 | nz.finance.yahoo.comThe 10 best dressed from the 2024 SAG AwardsFebruary 25, 2024 | finance.yahoo.comEarnings Update: Indivior PLC (LON:INDV) Just Reported Its Yearly Results And Analysts Are Updating Their ForecastsFebruary 22, 2024 | seekingalpha.comIndivior PLC 2023 Q4 - Results - Earnings Call PresentationFebruary 22, 2024 | lse.co.ukTOP NEWS: Indivior swings to profit as eyes primary listing move to USFebruary 22, 2024 | markets.businessinsider.comIndivior Q4 Revenue SurgesFebruary 22, 2024 | reuters.comDrugmaker Indivior consults on moving primary listing from London to USFebruary 22, 2024 | finance.yahoo.comIndivior Announces Q4 / FY 2023 Financial ResultsFebruary 22, 2024 | prnewswire.comIndivior Announces Q4 / FY 2023 Financial ResultsFebruary 13, 2024 | finance.yahoo.comIndivior PLC (INDV.L)December 31, 2023 | finance.yahoo.comThose who invested in Indivior (LON:INDV) three years ago are up 118%December 20, 2023 | nasdaq.comIndivior Settles Patent Dispute With Teva Unit - Quick FactsDecember 20, 2023 | seekingalpha.comIndivior: Opioid Use Disorder Market Growth Could Deliver 59% UpsideDecember 5, 2023 | msn.comLondon court throws out Suboxone representative lawsuitNovember 20, 2023 | msn.comReckitt Benckiser, Indivior, ask London court to throw out Suboxone lawsuitNovember 17, 2023 | markets.businessinsider.comIndivior Announces Share Repurchase Program - Quick FactsNovember 16, 2023 | uk.finance.yahoo.comIndivior PLC (2IVB.MU)See More Headlines Receive INDV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today4/27/2024Next Earnings (Estimated)7/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:INDV CUSIPN/A CIK1625297 Webwww.indivior.com Phone804-379-1090Fax804-379-1215Employees1,164Year FoundedN/APrice Target and Rating Average Stock Price Target$36.00 High Stock Price Target$37.00 Low Stock Price Target$35.00 Potential Upside/Downside+104.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.01 Trailing P/E Ratio1,758.00 Forward P/E Ratio8.66 P/E GrowthN/ANet Income$2 million Net Margins0.44% Pretax Margin0.09% Return on Equity700.00% Return on Assets11.76% Debt Debt-to-Equity RatioN/A Current Ratio0.97 Quick Ratio0.86 Sales & Book Value Annual Sales$1.09 billion Price / Sales2.22 Cash Flow$1.85 per share Price / Cash Flow9.48 Book Value$0.37 per share Price / Book47.51Miscellaneous Outstanding Shares137,880,000Free FloatN/AMarket Cap$2.42 billion OptionableNot Optionable Beta0.46 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Mark CrossleyCEO & Executive DirectorMr. Ryan PreblickCFO & Executive DirectorDr. Christian HeidbrederChief Scientific OfficerMr. Jason ThompsonVice President of Investor RelationsMs. Cynthia CetaniChief Integrity & Compliance OfficerMr. Jeffrey W. Burris (Age 52)Chief Legal Officer Mr. Jon FogleChief Human Resources OfficerMr. Richard SimkinChief Commercial OfficerMr. Hillel WestChief Manufacturing & Supply OfficerMr. Vishal KaliaSVP of US Treatment Access, Support Programs & Business Insights and Chief Impact & Strategy OfficerMore ExecutivesKey CompetitorsJanux TherapeuticsNASDAQ:JANXCorcept TherapeuticsNASDAQ:CORTRhythm PharmaceuticalsNASDAQ:RYTMSummit TherapeuticsNASDAQ:SMMTArvinasNASDAQ:ARVNView All CompetitorsInstitutional OwnershipCannon Global Investment Management LLCBought 26,300 shares on 4/17/2024Ownership: 0.019%Artemis Investment Management LLPSold 1,690,880 shares on 4/16/2024Ownership: 0.714%Vanguard Group Inc.Bought 52,836 shares on 3/11/2024Ownership: 4.278%Goldman Sachs Group Inc.Sold 1,224,501 shares on 3/1/2024Ownership: 3.234%Royal London Asset Management Ltd.Bought 24,383 shares on 3/1/2024Ownership: 0.325%View All Institutional Transactions INDV Stock Analysis - Frequently Asked Questions Should I buy or sell Indivior stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Indivior in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" INDV shares. View INDV analyst ratings or view top-rated stocks. What is Indivior's stock price target for 2024? 2 analysts have issued twelve-month price targets for Indivior's stock. Their INDV share price targets range from $35.00 to $37.00. On average, they anticipate the company's share price to reach $36.00 in the next twelve months. This suggests a possible upside of 104.8% from the stock's current price. View analysts price targets for INDV or view top-rated stocks among Wall Street analysts. How have INDV shares performed in 2024? Indivior's stock was trading at $15.27 on January 1st, 2024. Since then, INDV shares have increased by 15.1% and is now trading at $17.58. View the best growth stocks for 2024 here. Are investors shorting Indivior? Indivior saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 201,800 shares, an increase of 15.8% from the March 31st total of 174,300 shares. Based on an average daily volume of 129,300 shares, the days-to-cover ratio is presently 1.6 days. Currently, 0.2% of the shares of the company are sold short. View Indivior's Short Interest. When is Indivior's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024. View our INDV earnings forecast. How were Indivior's earnings last quarter? Indivior PLC (NASDAQ:INDV) released its earnings results on Thursday, February, 22nd. The company reported $0.43 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.28 by $0.15. The business earned $293 million during the quarter, compared to analysts' expectations of $260 million. Indivior had a net margin of 0.44% and a trailing twelve-month return on equity of 700.00%. What guidance has Indivior issued on next quarter's earnings? Indivior updated its FY 2024 earnings guidance on Thursday, April, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.2 billion-$1.3 billion, compared to the consensus revenue estimate of $1.3 billion. Who are Indivior's major shareholders? Indivior's stock is owned by a variety of retail and institutional investors. Top institutional investors include Artemis Investment Management LLP (0.71%) and Cannon Global Investment Management LLC (0.02%). How do I buy shares of Indivior? Shares of INDV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INDV) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyProtect Your Bank Account Before It’s Too LateWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithJeff Bezos Just Humiliated Elon MuskInvestorPlaceBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indivior PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
